Compare BJDX & NUWE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BJDX | NUWE |
|---|---|---|
| Founded | 2015 | 1999 |
| Country | United States | United States |
| Employees | N/A | 38 |
| Industry | Medical Specialities | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0M | 1.7M |
| IPO Year | 2021 | N/A |
| Metric | BJDX | NUWE |
|---|---|---|
| Price | $1.90 | $1.13 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 11.1K | ★ 30.1K |
| Earning Date | 05-12-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 86.65 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $249,040.00 | N/A |
| Revenue This Year | N/A | $11.14 |
| Revenue Next Year | N/A | $18.51 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.63 | $0.19 |
| 52 Week High | $4.17 | $25.95 |
| Indicator | BJDX | NUWE |
|---|---|---|
| Relative Strength Index (RSI) | 48.33 | 40.53 |
| Support Level | $1.73 | $0.96 |
| Resistance Level | $2.10 | $1.19 |
| Average True Range (ATR) | 0.11 | 0.08 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 60.68 | 6.08 |
Bluejay Diagnostics Inc is a medical diagnostics company focused on improving patient outcomes using its Symphony System, a cost-effective, rapid, near-patient testing system for sepsis triage and monitoring of disease progression. Bluejay's first product candidate, an IL-6 Test for sepsis, is designed to provide accurate, reliable results in approximately 20 minutes from sample-to-result to help medical professionals make earlier and quicker triage/treatment decisions.
Nuwellis Inc is a medical technology company focused on developing, manufacturing, and commercializing a medical device used in ultrafiltration therapy, including the Aquadex FlexFlow and the Aquadex SmartFlow systems. The Aquadex Smartflow System removes excess fluid from patients suffering from fluid overload who have not responded to medical management, including diuretics. Nuwellis has one reportable segment: fluid overload.